Meeting details menu

Meeting Authors
Meeting Abstracts
Keynote lectures
Oral communications
Poster presentations
Special symposia
Other

Acta Physiologica Congress

Back

Acta Physiologica 2007; Volume 189, Supplement 653
The 86th Annual Meeting of The German Physiological Society
3/25/2007-3/28/2007
Hannover, Germany


HUMAN LLAMAS? VARIATION IN BLOOD OXYGEN TRANSPORT PROPERTIES OF MAN AT ALTITUDE
Abstract number: O21-1

Boning1 D

1Sportmedizin, Charit - Universittsmedizin Berlin

A rise in hemoglobin concentration ([Hb]) seems to be a reaction useful for survival and for performance in hypoxia as well as normoxia. But it increases blood viscosity and thus cardiac work as well as the risk of blood clotting. Enlarged cardiac output as alternative reaction only increases cardiac work. An evaluation of published data shows divergent results. In Caucasians [Hb] increases at altitude, but hemodilution does not reduce VO2. Also in the Andean population polycytemia is a regular effect but some investigations show negative correlations between health state and [Hb]. In the Arabian Highland the risk for thrombotic stroke increases with [Hb]. In Quechuas the drawback of the regular [Hb] increase for blood viscosity is compensated by low [fibrinogen]. Despite enlarged Hb mass trained highlanders in Colombia (2600 m) tend to lowered [Hb] compared to sedentary residents. The correlation between [Hb] and VO2 is weak or even lacking. Tibetans and Sherpas (4000 m) show only small increases in [Hb], Ethiopeans living at 3500 m of altitude possibly since 200000 years show no [Hb] increase and also no decrease of arterial O2 saturation. The latter is hardly explainable without a rise in Hb O2 affinity which has not been investigated until now. Possibly the Llama model of hypoxia adaptation (no [Hb] increase, small red cells, left shift of the O2 dissociation curve) is also used by human populations living since long time at altitude.

To cite this abstract, please use the following information:
Acta Physiologica 2007; Volume 189, Supplement 653 :O21-1

Our site uses cookies to improve your experience.You can find out more about our use of cookies in our standard cookie policy, including instructions on how to reject and delete cookies if you wish to do so.

By continuing to browse this site you agree to us using cookies as described in our standard cookie policy .

CLOSE